Allergan neurology, musculoskeletal news

Allergan settled a U.S. Department of Justice investigation into off-label use of Botox onabotulinumtoxinA during 2000-2005. The company pled guilty to a misdemeanor misbranding charge and has agreed to pay the federal government $375 million. Allergan will pay $225 million to resolve civil claims made by the federal government under the False Claims Act. Allergan also was required to dismiss its First Amendment lawsuit against the FDA which the company filed in October in the U.S. District Court for the District of Columbia (see BioCentury, Oct. 5, 2009). ...